- Home
- LNZA vs ONCY Comparison
LNZA vs ONCY Comparison
Compare LNZA & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNZA
- ONCY
- Stock Information
- Founded
- LNZA 2005
- ONCY 1998
- Country
- LNZA United States
- ONCY Canada
- Employees
- LNZA N/A
- ONCY N/A
- Industry
- LNZA Major Chemicals
- ONCY Pharmaceuticals and Biotechnology
- Sector
- LNZA Industrials
- ONCY Health Care
- Exchange
- LNZA Nasdaq
- ONCY Nasdaq
- Market Cap
- LNZA 43.7M
- ONCY 49.1M
- IPO Year
- LNZA N/A
- ONCY 1999
- Fundamental
- Price
- LNZA $0.20
- ONCY $0.42
- Analyst Decision
- LNZA Hold
- ONCY Strong Buy
- Analyst Count
- LNZA 2
- ONCY 4
- Target Price
- LNZA $2.00
- ONCY $4.33
- AVG Volume (30 Days)
- LNZA 988.3K
- ONCY 712.1K
- Earning Date
- LNZA 05-19-2025
- ONCY 05-14-2025
- Dividend Yield
- LNZA N/A
- ONCY N/A
- EPS Growth
- LNZA N/A
- ONCY N/A
- EPS
- LNZA N/A
- ONCY N/A
- Revenue
- LNZA $48,831,000.00
- ONCY N/A
- Revenue This Year
- LNZA $86.52
- ONCY N/A
- Revenue Next Year
- LNZA N/A
- ONCY N/A
- P/E Ratio
- LNZA N/A
- ONCY N/A
- Revenue Growth
- LNZA N/A
- ONCY N/A
- 52 Week Low
- LNZA $0.14
- ONCY $0.37
- 52 Week High
- LNZA $3.26
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- LNZA 39.55
- ONCY 31.64
- Support Level
- LNZA $0.22
- ONCY $0.54
- Resistance Level
- LNZA $0.27
- ONCY $0.45
- Average True Range (ATR)
- LNZA 0.03
- ONCY 0.04
- MACD
- LNZA 0.00
- ONCY -0.01
- Stochastic Oscillator
- LNZA 5.26
- ONCY 25.48
About LNZA LanzaTech Global Inc.
LanzaTech Global Inc is a carbon management company transforming waste carbon into sustainable fuels, fabrics, packaging, and nutrition. Its goal is to advance a circular economy where carbon is reused rather than wasted, reducing reliance on virgin fossil resources and supporting supply chain resilience. The company operates in North America, Europe, Middle East, Africa (EMEA), Asia, and Australia.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.